Scandinavian ChemoTech

Fourth quarter 2024                                                                                                                                                                                                                                             

• Net sales amounted to 2 041 KSEK (507)

• Profit/loss after financial items amounted to -3 167 KSEK (-5 148)

• Earnings per share amounted to -0,14 SEK (-0,35)

• Cash flow from operating activities amounted to -2 172 KSEK (-3 396)

Full year 2024                                                       

• Net sales amounted to 6 566 KSEK (2 822)

• Profit/loss after financial items amounted to -13 717 KSEK (-21 091)

• Earnings per share amounted to -0,66 SEK (-1,56)

• Cash flow from operating activities amounted to -13 145 KSEK (-18 227)

• All orders were delivered at the end of the period

Events during the reporting period

• ChemoTech’s Animal Care enters strategic collaboration with Norwegian Veterinary University’s Hospital for Equine Medicine

• Animal Care is heading towards a strong fourth quarter of 2024 in terms of sales.

• ChemoTech splits business units to boost cash flow and will suggest a new name for the Group

Events after the reporting period

• ChemoTech implements management changes to reduce costs and boost revenue

• ChemoTech’s Animal Care operations showed positive cashflow for 2024 in separate reporting

• ChemoTech restructures loans and doubles the duration to 12 months